Author:
Kavikondala Sushma,Haeussler Katrin,Wang Xuan,Spellman Anne,Bausch-Jurken Mary T.,Sharma Pawana,Amiri Mohammadreza,Krivelyova Anna,Vats Sonam,Nassim Maria,Kumar Nitendra,Van de Velde Nicolas
Abstract
ABSTRACTAimImmunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose COVID-19 vaccines may offer increased immunogenicity.Materials & methodsA pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50 or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes were seroconversion, total and neutralizing antibody titers, and cellular immune responses.ResultsmRNA-1273 was associated with a significantly higher seroconversion likelihood (relative risk, 1.11 [95% CI, 1.08, 1.14];P<0.0001;I2=66.8%) and higher total antibody titers (relative increase, 50.45% [95% CI, 34.63%, 66.28%];P<0.0001;I2=89.5%) versus BNT162b2. mRNA-1273 elicited higher but statistically nonsignificant relative increases in neutralizing antibody titers and cellular immune responses versus BNT162b2.ConclusionHigher-dose mRNA-1273 had increased immunogenicity versus BNT162b2 in IC patients.
Publisher
Cold Spring Harbor Laboratory
Reference164 articles.
1. mRNA vaccines for infectious diseases: principles, delivery and clinical translation;Nat Rev Drug Discov,2021
2. SPIKEVAX (mRNA-1273). Full Prescribing Information, Moderna, Inc., Cambridge, MA (2022).
3. COMIRNATY (BNT162b2). Full Prescribing Information, Pfizer/BioNTech, New York, NY (2022).
4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
5. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献